MUNICH, June 20, 2024 /PRNewswire/ — Rolls-Royce Power Systems (RRPS) and CATL are excited to announce a strategic cooperation that will bring the TENER product line to the EU and UK markets. The groundbreaking product is designed with safety in mind and, improvement of service life, efficiency, and availability. Depending on the product line and […]
Category Archives: Pr Newswire
NEW YORK, June 20, 2024 /PRNewswire/ — EaseUS is a leading provider of data backup & recovery, file transfer, and disk management solutions for Windows PC and server users. It has consistently delivered comprehensive and reliable products since its establishment. Recognizing the ever-changing customers’ demands, EaseUS Todo PCTrans 13.15 made some enhancements and now supports seamless file […]
Pr Newswire
Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association
19
Jun
Jun
Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain (DPNP) Investigators conclude that clinical outcomes of RELIEF-DPN 1 support commencement of Lexicon’s dose-ranging Phase 2b PROGRESS trial, currently enrolling patients THE WOODLANDS, Texas, June 19, 2024 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today […]
Pr Newswire
Calibre Scientific Acquires DCS, a German Provider of Antibodies, Reagents and Equipment Used in Immunohistochemistry
19
Jun
Jun
LOS ANGELES, June 19, 2024 (GLOBE NEWSWIRE) — Calibre Scientific is pleased to announce the acquisition of DCS Innovative Diagnostik-Systeme GmbH & Co. KG (“DCS” or the “Company”), a German supplier of reagents and equipment used in immunohistochemistry for the diagnostic, research, industrial, university and hospital industries, with a focus on clinical pathology and oncology […]
Pr Newswire
Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors
19
Jun
Jun
REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced the appointment of […]
19
Jun
Jun
Patent No. US 11,998,632 B2 (“Patent”) covers Avicanna’s self-emulsifying drug delivery system (“SEDDS”) oral cannabinoid composition and methods of treating neuropathic pain TORONTO, June 19, 2024 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is […]
19
Jun
Jun
June 19, 2024 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA) today announced that it has completed the cancellation of 4,437,164 of its shares. The cancelled shares were acquired as part of the completed EUR 1.5 billion share repurchase program for capital reduction purposes that was announced on July 26, 2021. Philips’ current […]
Golidocitinib is a first-in-class Janus kinase 1 (JAK1) only inhibitor approved for the treatment of r/r PTCL based on results from the multinational pivotal JACKPOT8B study. Golidocitinib monotherapy demonstrated superior and durable clinical benefits and a favorable safety profile in r/r PTCL patients, compared with existing treatment options. SHANGHAI, June 19, 2024 /PRNewswire/ — Dizal (SSE:688192), […]
BEIJING, June 19, 2024 /PRNewswire/ — The “618” Grand Promotion of 2024 has drawn to a close, a landmark event that has ushered in a new era of simplified shopping. This year’s event has eschewed the traditional pre-sales format in favor of an elongated promotional period designed to improve the consumer experience. E-commerce titans—Alibaba, JD, […]
SHANGHAI, June 19, 2024 /PRNewswire/ — GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced China’s National Medical Products Administration (NMPA) has approved the clinical trial application for GFH375 (VS-7375) in an open-label, multi-center phase I/II study targeting advanced solid tumor patients with KRAS G12D mutation. G12D mutation is […]